Our results indicate that the λF7 test construct decorated with the fused peptide gpD::GP2 successfully decreased the tumor size in prophylactic (P < 0.01) and therapeutic (P < 0.05) assays in comparison to the TN buffer. Here, ACKR1 is linked to neoplasm.